MedTrace Logo

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

NCT01150812 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2010-09-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of AZD8165 and the pharmacokinetics of the metabolite AZ12971554 and plasma levels of the prodrug AZD8165 after escalating single oral low doses.

Conditions

  • Thrombin Inhibition

Interventions

DRUG

AZD8165

Oral suspension, 2 mg/mL and 20 mg/mL, single doses

Sponsors & Collaborators

Principal Investigators

  • Ralph Schutz, MD · Quintiles, Inc.

  • Peter Held · AstraZeneca

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150812 on ClinicalTrials.gov